[vc_row full_width=”stretch_row” css=”.vc_custom_1538854766651{padding-top: 40px !important;}”][vc_column][vc_column_text]Market pretense in healthcare delivery has consequences: excess cost, ‘consumer’ confusion, and political acrimony

In December 2003, then Pres. George W. Bush signed Medicare Part D (the pharmacy benefit) into law.  It was essentially a partisan bill.  As detailed in the Boston Globe excerpt below, Medicare Part D was a small boon to some low-income seniors, but it came at a huge cost, including subsidies for private insurers and a give-away to Big Pharma (they were allowed to set their own prices for drugs sold to Medicare).  To make the pretense of market economics appear, the bill was deeply incoherent: “In the name of greater free-market competition, the legislation offers massive new subsidies to the pharmaceutical and insurance industries.  In the name of providing greater protection, it threatens Medicare’s guarantee of universal benefits.  And in the name of greater cost containment, it encourages the expansion of private plans that have, to date, not saved Medicare money, while creating new budgetary rules that could very well make Medicare less equitable and affordable down the road.”  You can not pretend that something is the case, when it manifestly is not so, without paying a price.  Fast forward fourteen years to the present.  Pro-Publica and the New York Times are reporting that health insurers commonly offer medication ‘coverage’ that is more expensive for the ‘consumer’ than simply buying the drug without using the insurance card, even if they make the purchase at a pharmacy owned by the insurer.  The pretext of encouraging market economics in medication buying and selling, allegedly passed into law 14 years ago, is now haunting the homes and hospitals of American patients.  Let’s stop calling this market economics.  Let’s call this what it really is:  corporate welfare at the expense of American patients.

The New York Times
December 9, 2017

Prescription Drugs May Cost More With Insurance Than Without It
By Charles Ornstein and Katie Thomas

In an era when drug prices have ignited public outrage and insurers are requiring consumers to shoulder more of the costs, people are shocked to discover they can sometimes get better deals than their own insurers. Behind the seemingly simple act of buying a bottle of pills, a host of players — drug companies, pharmacies, insurers and pharmacy benefit managers — are taking a cut of the profits, even as consumers are left to fend for themselves, critics say.

Pharmacy benefit managers, the companies that deal with drug benefits on behalf of insurers, often do negotiate better prices for consumers, particularly for brand-name medications, but that’s not necessarily true for some generic drugs.

As a result of these complicated layers of negotiation — which are not made public — different insurers end up paying different prices for individual drugs. Further compounding confusion for consumers, some insurers require a set co-payment for each prescription — say, $15 or $20 — even when the insurer reimburses the pharmacy at a much cheaper rate.

Consumers also may face penalties if they don’t use their insurance and pay cash to save money. In many cases, insurers won’t let them apply those purchases to a deductible or out-of-pocket spending maximum.

Still, many find that leaving their prescription card at home is worth it. Some have found a better deal even at pharmacies that are owned by their drug plan, like CVS.

Even as more Americans have health insurance since the Affordable Care Act was passed, insurers are increasingly asking consumers to pay a larger share of their costs. In 2016, about five million people in Medicare hit a stage in which they had to pick up a greater share of their expenses.

Consumers may also pay more if they are covered by plans that require them to pay a set co-payment, no matter the cash price. In some of those cases, the insurers require the pharmacies to send them the difference between what they collect from the consumer and what the insurers have agreed to reimburse the pharmacies.

https://www.nytimes.com/2017/12/09/health/drug-prices-generics-insurance.html

***

Boston Globe
December 7, 2003

Poison pill
By Jacob S. Hacker and Theodore R. Marmor

Tomorrow, President Bush is set to sign Medicare’s biggest overhaul in 38 years into law. But after watching the shrill yet perfunctory debate that culminated last week in the passage of the bill, even close observers of Washington politics can be forgiven for wondering just what exactly it was all about. On one side, congressional Republicans and President Bush described the $400-billion legislation as a moderate, sensible means of providing long-overdue drug coverage to seniors.

On the other, Democratic opponents — including most House Democrats, Senate minority leader Tom Daschle, and Senator Ted Kennedy, who led an unsuccessful filibuster — decried it as a monstrous giveaway to insurers and drug companies. They also charged that it was a “Trojan horse” aimed at crippling Medicare’s universal benefits in order to foster go-it-alone competition.

All this becomes more understandable when one recognizes that the bill is really two bills. The first provides a much-needed, if modest and excessively complex, drug benefit. But while this new benefit is generous for some low-income seniors, it will end up raising out-of-pocket drug costs for other poor beneficiaries. And because it is poorly designed and does not include effective ways of controlling drug costs, the plan will ultimately leave most seniors little better off than they are today, and some worse off.

The second, darker side of the new Medicare bill is a slew of changes that have little or nothing to do with drug coverage and everything to do with special-interest demands and ideological animus toward Medicare. These include huge new subsidies for private insurers, and provisions that ensure that drug companies will be spared from their greatest fear: that Medicare will use its massive buying power to demand reductions in drug prices. Perhaps most ominous, the bill also contains elements that favor private plans and risk further degeneration of Medicare’s all-in-the-same-boat structure.

What is most striking about the bill is not the consistency of its vision, but its deep incoherence. In the name of greater free-market competition, the legislation offers massive new subsidies to the pharmaceutical and insurance industries. In the name of providing greater protection, it threatens Medicare’s guarantee of universal benefits. And in the name of greater cost containment, it encourages the expansion of private plans that have, to date, not saved Medicare money, while creating new budgetary rules that could very well make Medicare less equitable and affordable down the road.

Behind these glaring inconsistencies lies the one great fact of contemporary American politics: partisan and ideological polarization.

It’s also certain to cause political conflict — which may be the bill’s ultimate contradiction. Republicans hope to take off the table an issue with which they have been battered for years, and they may well do so through 2006. But by pushing through such an unwieldy bill, they are virtually ensuring that Medicare will be the biggest issue in American politics in the coming decades. Sadly, at the present juncture, that seems to promise more acrimony, confusion, and disappointment, rather than the constructive steps forward that Medicare so desperately needs.

http://www.pnhp.org/news/2003/december/poison_pill.php

[/vc_column_text][/vc_column][/vc_row]